Paradies Lagardere Default

Genentech pioneered the biotechnology industry and revolutionized treatment for some of the most complex health problems. For nearly 50 years, the company has pursued groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases. Founded in 1976 by venture capitalist Robert A. Swanson and biochemist Dr. Herbert W. Boyer, Genentech has consistently pushed the boundaries of what is possible in biomedical research. The company's transformational discoveries include the first personalized medicine for cancer and the first medicine for primary progressive multiple sclerosis. Today, Genentech operates as a member of the Roche Group, galvanizing the greatest minds across their business to make lasting improvements in healthcare. Their approach includes novel customer engagement strategies, state-of-the-art manufacturing facilities, and integrating AI for molecule discovery. With a $50 billion commitment to U.S. manufacturing and R&D, Genentech remains dedicated to leveling barriers to clinical trial participation, driving inclusive research, and optimizing health outcomes for all patients.

Drees & Sommer exists to create a future worth living by transforming how the built environment is designed, constructed, and operated. The construction and real estate industries account for nearly 40% of global carbon emissions, yet traditional approaches remain fragmented, inefficient, and unsustainable. Drees & Sommer tackles this challenge head-on by providing integrated consulting and implementation services that unite vision with reality - delivering projects that are economically viable, ecologically responsible, and digitally enabled. Since 1970, the company has grown from a small Stuttgart engineering office into a global partner-managed consultancy with 6,500 professionals across 70+ cities. Their interdisciplinary teams work on 6,872+ projects worldwide, uniting apparent opposites: tradition and innovation, economy and ecology, analog and digital, efficiency and well-being. As a sustainability pioneer and digitalization driver, Drees & Sommer doesn't just advise clients - they implement solutions that measurably reduce environmental impact while creating lasting value. From carbon-neutral buildings to resilient infrastructure and future-proof industrial facilities, they're proving that sustainable development isn't just necessary - it's the foundation of competitive advantage in a changing world.

Trulieve is an industry-leading, vertically integrated cannabis company and multi-state operator in the United States. As the first and largest fully licensed medical cannabis company in Florida, Trulieve operates a seed-to-sale model, cultivating and producing all products in-house before distributing them through a network of branded dispensaries across multiple states. The company is publicly traded on the Canadian Securities Exchange (TRUL) and OTCQX Best Market (TCNNF), demonstrating its position as a major player in the U.S. cannabis market. Trulieve's product portfolio is designed to alleviate seizures, severe and persistent muscle spasms, pain, nausea, loss of appetite, and other symptoms associated with serious medical conditions such as cancer. The company offers both low-THC/CBD products for non-euphoric care and traditional cannabis products. With established operations in states including Florida, Arizona, Pennsylvania, and Massachusetts, Trulieve has generated over $1.2 billion in annual revenue and continues expanding its market presence through strategic acquisitions and organic growth.

At Bunge, we believe our strength lies in our passionate, bold, and driven teams who work collaboratively across the globe to connect farmers to consumers. With more than 200 years of experience, our approximately 37,000 colleagues operate as One Team - fostering inclusion, collaboration, and respect - while driving for excellence through agility, innovation, and efficiency. We're people who see change as an opportunity to evolve, who enjoy taking ownership of our work, and who embrace meaningful purpose in everything we do. Our culture is built on doing what's right: acting safely, ethically, and sustainably as we deliver essential food, feed, and fuel to the world. We listen, empower, develop, and reward our people with programs that enhance our workplace environment - from diversity and inclusion initiatives to career development and wellness resources. Whether you're in grain origination, oilseed processing, or creating innovative plant-based solutions, you'll find a team that leads the way while staying grounded in integrity and sustainability.

Servier was founded in 1954 when Jacques Servier created a pharmaceutical company in Orléans with a vision to serve patient health. What started as a single entity has evolved into a global independent pharmaceutical group governed by a unique non-profit foundation, a structure that enables the company to maintain a long-term vision free from investor pressure. This distinctive governance model allows Servier to reinvest all profits into a single priority: therapeutic progress to serve patient needs worldwide. Today, the company operates in more than 130 countries with over 21,900 employees representing 50+ nationalities, treating approximately 100 million patients daily with Servier Group medicines. The company has strategically transformed from its origins as a global leader in cardiometabolism to become an oncology powerhouse, dedicating 70% of its R&D budget to oncology while maintaining its strong cardiovascular franchise. Servier invests close to 20% of its brand-name medicine revenue in research and development, focusing on difficult-to-treat cancers, rare neurological disorders, and cardiovascular diseases. This commitment is evidenced by its growing portfolio of first-in-class and best-in-class medicines, including groundbreaking treatments like TIBSOVO and VORANIGO. Servier operates six research centers and 19 International Centers for Therapeutic Research, embodying values of daring to innovate, caring deeply, committing to success, and growing through shared efforts as it works toward its 2030 ambition to impact society by creating benefit for patients and making the world more sustainable.

At Roche, we believe that advancing science requires deep collaboration and an unwavering commitment to patients. As the world's largest biotech company and a leading provider of in-vitro diagnostics, we combine our unique strengths in pharmaceuticals and diagnostics to transform healthcare. Our cross-functional teams work together across borders and disciplines, focusing on preventing, stopping, or curing diseases with the highest societal burden. We empower our people with integrity, courage, and passion to explore new possibilities and take calculated risks that lead to breakthrough innovations. For over 125 years, our culture has been defined by scientific excellence and a relentless pursuit of better health outcomes. We operate with a long-term vision, making sustainable investments in R&D and partnerships that span over 250 external collaborations. Our ways of working foster agility and networked responses to the evolving needs of patients worldwide. Whether in our research labs, manufacturing facilities, or offices, Roche employees thrive in an environment where diverse perspectives fuel innovation and where we measure success by the time we give patients with the people they love.